


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (Currently Amended) A compound of Formula (I), or a pharmaceutically acceptable salt thereof;

wherein the compound of Formula (I) is:

















(I)


wherein:










R<sub>m</sub> is a hydrogen or a lower alkyl group;

R<sub>n</sub> is:









s is an integer of 0 or 1;

X is:

- (1)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-\text{V}-\text{B}-\text{T}-(\text{CR}_4\text{R}_4')_p-\text{ONO}_2;$
- (2)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-\text{T}-\text{C}(\text{O})-(\text{CR}_4\text{R}_4')_o-(\text{CH}_2)-\text{ONO}_2;$
- (3)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-\text{T}-(\text{CH}_2)_q-\text{V}-(\text{CR}_4\text{R}_4')_q-(\text{CH}_2)-\text{ONO}_2;$
- (4)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-\text{V}-(\text{CH}_2)_q-\text{V}-(\text{CR}_4\text{R}_4')_q-(\text{CH}_2)-\text{ONO}_2;$
- (5)  $-\text{Y}-(\text{CR}_4\text{R}_4')_o-(\text{W})_q-(\text{CR}_4\text{R}_4')_o-(\text{CH}_2)-\text{ONO}_2;$
- (6)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-\text{V}-(\text{CH}_2)_o-(\text{W})_q-(\text{CR}_4\text{R}_4')_q-(\text{CH}_2)-\text{ONO}_2;$
- (7)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-(\text{W})_q-(\text{T})_o-(\text{CR}_4\text{R}_4')_o-(\text{CH}_2)-\text{ONO}_2;$
- (8)  $-\text{Y}-(\text{CR}_4\text{R}_4')_q-\text{C}(\text{Z})-\text{V}-(\text{CR}_4\text{R}_4')_q-(\text{CH}_2)-\text{ONO}_2;$
- (9)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-\text{V}-(\text{CR}_4\text{R}_4')_p-(\text{CH}_2)-\text{ONO}_2;$  or
- (10)  $-\text{Y}-(\text{CR}_4\text{R}_4')_p-\text{V}-(\text{CH}_2)_q-(\text{T})_o-(\text{CR}_4\text{R}_4')_q-(\text{CH}_2)-\text{ONO}_2;$

$\text{R}_4$  and  $\text{R}_4'$  at each occurrence are independently a hydrogen, lower alkyl group, -OH, - $\text{CH}_2\text{OH}$ , - $\text{ONO}_2$ , - $\text{NO}_2$  or - $\text{CH}_2\text{ONO}_2$ ; or  $\text{R}_4$  and  $\text{R}_4'$  taken together with the carbon atom to which they are attached are a cycloalkyl group or a heterocyclic ring;

V is - $\text{C}(\text{O})-\text{T}-$ , - $\text{T}-\text{C}(\text{O})-$ , - $\text{T}-\text{C}(\text{O})-\text{T}$  or  $\text{T}-\text{C}(\text{O})-\text{C}(\text{O})-\text{T}$ ;

W is a covalent bond or a carbonyl group;

T at each occurrence is independently an oxygen,  $(\text{S}(\text{O})_o)_o$  or  $\text{NR}_j$ ;

$\text{R}_j$  is a hydrogen, an alkyl group, an aryl group, a heterocyclic ring, an alkylcarbonyl group, an alkylaryl group, an alkylsulfinyl group, an alkylsulfonyl group, an arylsulfinyl group, an arylsulfonyl group, a sulfonamido group, a N-alkylsulfonamido group, a N,N-diarylsulfonamido group, a N-arylsulfonamido group, a N-alkyl-N-arylsulfonamido group, a carboxamido group or a hydroxyl group;

p at each occurrence is independently an integer from 1 to 6;

q at each occurrence is independently an integer from 1 to 3;

o at each occurrence is independently an integer from 0 to 2;

Y is oxygen or sulfur (-S-);

B is either phenyl or  $(\text{CH}_2)_o$ ;

Q' is a cycloalkyl group, a heterocyclic ring or an aryl group;

Z is (=O), (=N- $\text{OR}_5$ ), (=N- $\text{NR}_5\text{R}'_5$ ) or (=CR<sub>5</sub>R'<sub>5</sub>);

M and M' are each independently  $-\text{O}^- \text{H}_3\text{N}^+-(\text{CR}_4\text{R}'_4)_q-\text{CH}_2\text{ONO}_2$  or  $-\text{T}-(\text{CR}_4\text{R}'_4)_o-\text{CH}_2\text{ONO}_2$ ;

$R_5$  and  $R_5'$  at each occurrence are independently a hydrogen, a hydroxyl group, an alkyl group, an aryl group, an alkylsulfonyl group, an arylsulfonyl group, a carboxylic ester, an alkylcarbonyl group, an arylcarbonyl group, a carboxamido group, an alkoxyalkyl group, an alkoxyaryl group, a cycloalkyl group or a heterocyclic ring; and

with the proviso that for X in the compounds of Formulas (I):

when Y is oxygen or sulfur in Formula 5, and W is a covalent bond, at least one  $R_4$  or  $R_4'$  must be  $-OH$ ,  $-ONO_2$ ,  $-NO_2$  or  $-CH_2ONO_2$  or  $R_4$  and  $R_4'$  taken together with the carbon atom to which they are attached are a cycloalkyl group or a heterocyclic ring;


when Y is oxygen or sulfur in Formula 7, T is  $-N(CH_3)$ , W is a covalent bond and  $R_4$  and  $R_4'$  are hydrogen, p cannot be the integer 2, and o cannot be the integer 1 in  $-(CR_4R_4')_o$ ;

when Y is oxygen or sulfur in Formula 7, W is a covalent bond, T is oxygen and o is the integer 1, at least one  $R_4$  or  $R_4'$  must be  $-OH$ ,  $-NO_2$  or  $-CH_2ONO_2$  or  $R_4$  and  $R_4'$  taken together with the carbon atom to which they are attached are a cycloalkyl group or a heterocyclic ring.


2. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

3. (Previously Presented) The compound of claim 1, wherein X is:


(1)




(2)




(3)




(4)




(5)




(6)




(7)




(8)




(9)




(10)




(11)




(12)




(13)




(14)




(15)




(16)




(17)




(18)



(19)



(20)



wherein:

$\text{Y}'$  is oxygen or sulfur;

T' is oxygen, sulfur or NR<sub>6</sub>;

X<sub>5</sub> is oxygen, (S(O)<sub>0</sub>)<sub>0</sub> or NR<sub>6</sub>;

R<sub>6</sub> is a hydrogen, a lower alkyl group, an aryl group;

n' and m' are each independently an integer from 0 to 10; and

o is as defined herein.

4. (Currently Amended) The compound of claim 1, wherein the compound of Formula (I) is ~~a nitrosated acetometacin, a nitrosated aceclofenac, a nitrosated alminoprofen, a nitrosated amfenac, a nitrosated bendazac, a nitrosated benoxaprofen, a nitrosated bromfenac, a nitrosated bucloxic acid, a nitrosated butibufen, a nitrosated carprofen, a nitrosated cinmetacin, a nitrosated clopirac, a nitrosated diclofenac, a nitrosated etodolac, a nitrosated felbinac, a nitrosated fencloxic acid, a nitrosated fenbufen, a nitrosated fenoprofen, a nitrosated fentiazac, a nitrosated flunoxaprofen, a nitrosated flurbiprofen, a nitrosated ibufenac, a nitrosated ibuprofen, a nitrosated indomethacin, a nitrosated isofezolac, a nitrosated isoxepac, a nitrosated indoprofen, a nitrosated ketoprofen, a nitrosated lonazolac, a nitrosated loxoprofen, a nitrosated metiazinic acid, a nitrosated mofezolac, a nitrosated mioprofen, a nitrosated naproxen, a nitrosated exaprozin, a nitrosated pirozolac, a nitrosated pirprofen, a nitrosated pranoprofen, a nitrosated protizinic acid, a nitrosated salicylamide, a nitrosated sulindac, a nitrosated suprofen, a nitrosated susibuzone, a nitrosated tiaprofenic acid, a nitrosated tolmetin, a nitrosated xenbucin, a nitrosated ximoprofen, a nitrosated zaltoprofen, a nitrosated zomepirac; the compound of Formula II is a nitrosated aspirin, a nitrosated acetometein, a nitrosated bumadizone, a nitrosated carprofenac, a nitrosated clidanac, a nitrosated diflunisal, a nitrosated enfenamic acid, a nitrosated fendosal, a nitrosated flufenamic acid, a nitrosated flunixin, a nitrosated gentisic acid, a nitrosated ketorolac, a nitrosated meclofenamic acid, a nitrosated mefenamic acid, a nitrosated mesalamine, a nitrosated niflumic acid, a nitrosated salsalate, a nitrosated tolfenamic acid or a nitrosated tropensin substituted with at least one -NO<sub>2</sub> group.~~

5 – 54 (Cancelled).

55. (Previously Presented) A compound selected from the group consisting of (N-methyl-N-(2-(nitrooxy)ethyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate; (N-ethyl-N-(2-(nitrooxy)ethyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate; (N-methyl-N-(((2-(nitrooxy)ethyl)oxycarbonyl)methyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;

(N-methyl-N-(((3-(nitrooxy)propyl)oxycarbonyl)methyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;  
(N-methyl-N-((N-(2-(nitrooxy)ethyl)carbamoyl)methyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;  
((2-(nitrooxy)ethyl)oxycarbonyl)methyl 2-(6-methoxy-2-naphthyl)propanoate;  
(N-(3-(nitrooxy)propyl)carbamoyl)methyl 2-(6-methoxy-2-naphthyl)propanoate;  
((2-((2-(nitrooxy)ethyl)sulfonyl)ethyl)oxycarbonyl)methyl 2-(6-methoxy-2-naphthyl)propanoate;  
(2S)-2-(6-methoxy(2-naphthyl))-N-((N-(2-(nitrooxy)ethyl)carbamoyl) methoxy)propanamide;  
(N-methyl-N-(3-(nitrooxy)propyl)carbamoyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate;  
2-((2S)-2-(6-methoxy(2-naphthyl))propanoyloxy)ethyl 3-(nitrooxy)-propyl ethane-1,2-dioate;  
N-((2S)-2-(6-methoxy(2-naphthyl))propanoylamino)-4 (nitrooxy)butanamide;  
or a pharmaceutically acceptable salt thereof.

56. (Withdrawn) A composition comprising at least one compound of claim 55 and a pharmaceutically acceptable carrier.

57. (Cancelled)

58. (Cancelled)